MUC1 and neoplasm: Some of anti-MUC1 mAbs, for instance 115D8, are marketed world-wide and have been used as a standard clinical tool to monitor tumour burden in breast cancer for nearly 30 years (CA15-3)3, even though the precise epitope structure in the MUC1 detected by the antibody remains unknown.